In patients with ductal carcinoma in situ (DCIS), HER-2/neu-targeted vaccination induced HER-2/neu-specific IFN-γ producing T cell responses and resulted in the inhibition of DCIS as well as the induction of HER-2/neu antigen loss [18,19]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.